Cases & Deals

Chiesi acquires three hospital products from The Medicines Company

Clients Chiesi Farmaceutici S.p.A.

Jones Day advised Chiesi Farmaceutici S.p.A., a pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets, in its acquisition of three cardiovascular products -- Kengreal® (cangrelor), Cleviprex® (clevidipine), and rights to Argatroban® for Injection –- from The Medicines Company. The Medicines Company received approximately $262 million in cash at closing, and is entitled to receive up to $480 million in sales-based milestone and royalty payment obligations.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.